MedTrace Logo

Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC

NCT01215474 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2011-06-16

No results posted yet for this study

Summary

While current mutational analyses comprise exons 19 and 21 in which the majority of EGFR-mutations occur, this study aims at investigating the relevance of exon 18 and 20 mutations. Therefore, the investigators analyse 500 routine tumor samples with respect to the above mentioned exons and correlate the results to the clinical outcome. This approach will enable us to potentially identify patients that might in the future benefit from targeted therapy (EGFR-inhibition).

Conditions

  • Mutations in Exons 18 to 21

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Charite University, Berlin, Germany

    collaborator OTHER

  • Provitro GmbH

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01215474 on ClinicalTrials.gov